| All patients | Patients with ASCVD | Patients without ASCVD | ||||||
---|---|---|---|---|---|---|---|---|---|
 | Dapagliflozin (N = 9586) | Empagliflozin (N = 9586) | ASMD | Dapagliflozin (N = 2401) | Empagliflozin (N = 2434) | ASMD | Dapagliflozin (N = 7185) | Empagliflozin (N = 7152) | ASMD |
Age, mean (SD) years | 59.9 (11.6) | 60.0 (12.0) | 0.01 | 63.6 (10.3) | 63.8 (10.8) | 0.01 | 58.6 (11.7) | 58.7 (12.2) | 0.01 |
Female, % | 40.2 | 40.2 | 0.01 | 28.0 | 27.7 | 0.05 | 44.3 | 44.5 | < 0.01 |
HbA1c, mean (SD) % | 8.7 (1.6) | 8.7 (1.7) | < 0.01 | 8.6 (1.6) | 8.5 (1.7) | 0.04 | 8.8 (1.6) | 8.8 (1.8) | <0.01 |
SBP, mean (SD) mmHg | 140.0 (19.3) | 140.0 (19.7) |  < 0.01 | 138.7 (19.9) | 137.9 (20.0) | 0.04 | 140.4 (19.1) | 140.7 (19.6) | < 0.01 |
DBP, mean (SD) mmHg | 78.7 (12.1) | 78.6 (12.0) | < 0.01 | 77.9 (12.2) | 77.1 (12.0) | 0.06 | 79.0 (12.1) | 79.2 (12.0) |  0.01 |
eGFR, mean (SD) ml/min/1.73 m2 | 92.8 (27.1) | 92.3 (31.6) | 0.01 | 86.3 (25.2) | 84.4 (27.9) | 0.07 | 94.9 (27.4) | 95.1 (32.6) | < 0.01 |
Hospital level, % |  |  | 0.03 |  |  | < 0.01 |  |  | 0.03 |
 Medical centers | 54.4 | 54.5 |  | 55.6 | 55.9 |  | 54.0 | 54.0 |  |
 Regional hospitals | 27.2 | 26.6 |  | 29.2 | 29.1 |  | 26.6 | 25.8 |  |
 District hospitals | 18.4 | 18.9 |  | 15.3 | 15.0 |  | 19.5 | 20.2 |  |
Specialty of prescriber, % | Â | Â | 0.03 | Â | Â | 0.02 | Â | Â | 0.03 |
 Metabolism & Endocrinology | 58.0 | 57.5 |  | 32.8 | 34.1 |  | 66.4 | 65.4 |  |
 Cardiology | 28.9 | 28.9 |  | 55.8 | 54.5 |  | 19.9 | 20.2 |  |
 Others | 13.2 | 13.6 |  | 11.5 | 11.5 |  | 13.8 | 14.4 |  |
Previous hospitalizations, % | 15.3 | 15.1 | < 0.01 | 28.7 | 29.8 | 0.02 | 10.8 | 10.1 | 0.02 |
ASCVD, % | 25.1 | 25.4 |  < 0.01 | 100.0 | 100.0 | – |  |  |  |
 Coronary heart disease | 21.3 | 21.7 | 0.01 | 85.1 | 85.6 | 0.02 | – | – | – |
 Ischemic stroke | 3.9 | 3.3 | 0.03 | 15.4 | 13.2 | 0.06 | – | – | – |
 Peripheral artery disease | 1.3 | 1.5 | 0.02 | 5.0 | 6.0 | 0.04 | – | – | – |
Comorbidity, % | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Hypertension | 67.6 | 68.0 | < 0.01 | 76.5 | 76.8 | < 0.01 | 64.6 | 65.0 | < 0.01 |
 Hyperlipidemia | 72.6 | 72.3 | < 0.01 | 72.4 | 71.8 | 0.01 | 72.6 | 72.5 | < 0.01 |
 Heart failure | 5.7 | 5.8 | < 0.01 | 14.5 | 14.6 | < 0.01 | 2.7 | 2.8 | < 0.01 |
 Atrial fibrillation | 3.2 | 3.3 | < 0.01 | 5.4 | 4.6 | 0.03 | 2.5 | 2.9 | 0.02 |
 Diabetic retinopathy | 8.0 | 7.8 | < 0.01 | 6.6 | 6.9 | 0.01 | 8.5 | 8.2 | 0.01 |
 Diabetic neuropathy | 9.0 | 8.3 | 0.02 | 7.6 | 7.6 | < 0.01 | 9.5 | 8.5 | 0.03 |
 Diabetic nephropathy | 23.8 | 23.8 | < 0.01 | 16.7 | 18.1 | 0.04 | 26.2 | 25.8 | 0.01 |
 COPD | 3.1 | 3.1 | < 0.01 | 5.3 | 5.3 | < 0.01 | 2.3 | 2.4 | < 0.01 |
 Liver disease | 17.2 | 17.6 | 0.01 | 12.2 | 12.2 |  < 0.01 | 18.8 | 19.4 | 0.01 |
 Depression | 1.5 | 1.6 | < 0.01 | 1.3 | 1.8 | 0.04 | 1.6 | 1.5 | < 0.01 |
 Schizophrenia | 0.4 | 0.4 | < 0.01 | 0.3 | 0.3 |  < 0.01 | 0.5 | 0.5 | < 0.01 |
 Cancer | 6.0 | 6.0 | < 0.01 | 5.3 | 6.2 | 0.04 | 6.3 | 5.9 | 0.02 |
CCI, mean (SD) scores | 2.5 (1.5) | 2.5 (1.5) | 0.01 | 2.8 (1.7) | 2.8 (1.7) | 0.05 | 2.4 (1.4) | 2.4 (1.4) | < 0.01 |
Co-medications, % | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Anti-platelet agents | 32.8 | 32.7 |  < 0.01 | 77.8 | 79.6 | 0.04 | 17.7 | 16.8 | 0.02 |
 Anti-coagulant agents | 3.3 | 3.4 |  < 0.01 | 5.3 | 5.0 | 0.01 | 2.6 | 2.9 | 0.02 |
 Beta blockers | 28.4 | 28.5 | < 0.01 | 55.3 | 55.3 | < 0.01 | 19.4 | 19.3 | < 0.01 |
 ACEI / ARB | 60.7 | 61.1 | < 0.01 | 74.6 | 72.7 | 0.04 | 56.1 | 57.1 | 0.02 |
 Calcium channel blockers | 40.3 | 41.2 | 0.02 | 50.5 | 45.9 | 0.09 | 36.9 | 39.6 | 0.06 |
 Spironolactone | 2.5 | 2.3 | 0.01 | 4.5 | 3.8 | 0.04 | 1.8 | 1.8 | < 0.01 |
 Other diuretics | 9.0 | 9.6 | 0.02 | 13.7 | 13.7 | < 0.01 | 7.5 | 8.1 | 0.03 |
 Digoxin | 1.1 | 1.1 | < 0.01 | 2.1 | 1.4 | 0.05 | 0.8 | 0.9 | 0.02 |
 Nitrate | 6.3 | 6.8 | 0.02 | 19.6 | 20.3 | 0.02 | 1.9 | 2.2 | 0.02 |
 Statin | 66.3 | 66.2 | < 0.01 | 77.0 | 79.3 | 0.06 | 62.7 | 61.7 | 0.02 |
 Fibrate | 9.1 | 10.0 | 0.03 | 8.1 | 8.8 | 0.02 | 9.4 | 10.4 | 0.03 |
 Ezetimibe | 11.6 | 11.8 | < 0.01 | 14.7 | 15.6 | 0.03 | 10.6 | 10.5 | < 0.01 |
 Metformin | 87.9 | 87.7 | < 0.01 | 86.8 | 86.0 | 0.02 | 88.2 | 88.2 | < 0.01 |
 Sulfonylurea | 54.8 | 54.5 |  < 0.01 | 55.1 | 53.1 | 0.04 | 54.7 | 55.0 |  < 0.01 |
 DPP4 inhibitors | 56.6 | 56.9 | < 0.01 | 56.6 | 54.5 | 0.04 | 56.7 | 57.7 | 0.02 |
 Acarbose | 16.1 | 15.7 | 0.01 | 18.2 | 16.1 | 0.05 | 15.4 | 15.5 | < 0.01 |
 Glinides | 1.8 | 2.1 | 0.02 | 1.4 | 2.1 | 0.05 | 1.9 | 2.1 | 0.01 |
 Thiazolidinediones | 22.2 | 21.9 | < 0.01 | 20.6 | 21.2 | 0.01 | 22.7 | 22.2 | 0.01 |
 GLP-1 RAs | 0.9 | 0.9 | < 0.01 | 0.8 | 0.6 | 0.02 | 1.0 | 1.0 | < 0.01 |
 Insulins | 16.7 | 16.7 | < 0.01 | 14.0 | 14.5 | 0.01 | 17.6 | 17.5 | < 0.01 |
 NSAID | 7.9 | 8.0 | < 0.01 | 8.3 | 8.0 | 0.01 | 7.8 | 8.0 | < 0.01 |